Renishaw has produced a titanium port by metal 3D printing / Additive Manufacturing for use in a ground-breaking clinical trial. The device enables the precise delivery of a new drug candidate, Glial Cell Line Derived Neurotrophic Factor (GDNF), directly into the brain of individuals with Parkinsonâs disease, with the aim to regenerate dying dopamine brain cells and thereby improve symptoms.
Read more ->
















